Imaging amyloid pathology in the living brain

Current Medical Imaging Reviews

Volumn 4, Issue 1, 2008, Pages 56-62

  Okamura, Nobuyuki ^a   Furumoto, Shozo ^b   Arai, Hiroyuki ^a   Iwata, Ren ^b   Yanai, Kazuhiko ^a   Kudo, Yukitsuka ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid; Molecular imaging; Neurofibrillary tangle; Positron emission tomography (PET); Senile plaque

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONITRILE F 18; 2,3 DIHYDRO 1H IMIDAZO[1,2 B]PYRAZOLE; ACRIDINE ORANGE; AMYLOID; AMYLOID BETA PROTEIN; BENZOFURAN DERIVATIVE; BENZOXAZOLE DERIVATIVE; BETA SECRETASE INHIBITOR; BF 125; BF 126; BF 133; BF 140; BF 145; BF 168; BF 180; BF 185; BF 191; BF 208; BF 227; BF 227 C 11; CHRYSAMINE G; CONGO RED; CONGO RED DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; RADIOPHARMACEUTICAL AGENT; SB 13; SB 13 C 11; STILBENE; THIOFLAVINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN DISEASE; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG STRUCTURE; DRUG UPTAKE; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; MOLECULAR IMAGING; NEUROPATHOLOGY; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 39049168274     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340508783502840     Document Type: Review

References (45)

1. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120: 545-555.
2. Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 2001; 56: 361-367.
3. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
4. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's diseas. Neurobiol Aging 1994; 691-698.
5. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging 1995; 16: 541-548.
6. Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ, Lee VM. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 7609-7614.
7. Zhuang ZP, Kung MP, Hou C, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001;44:1905-1914.
8. Klunk WE, Bacskai BJ, Mathis CA, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-XO4, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002; 61: 797-805.
9. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 24-35.
10. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001; 21: RC189.
11. Agdeppa ED, Kepe V, Petri A, et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-6-(2-(18)F]fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience 2003; 117: 723-730.
12. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 2004; 10: 1469-1492.
13. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001; 69: 1471-1484.
14. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23: 2086-2092.
15. Kung MP, Hou C, Zhuang ZP, et al. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 2002; 956: 202-210.
16. Kung HF, Kung MP, Zhuang ZP, et al. Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol 2003; 5: 418-426.
17. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003; 30: 565-571.
18. Ono M, Kawashima H, Nonaka A, et al. Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem 2006; 49: 2725-2730.
19. Suemoto T, Okamura N, Shiomitsu T, et al. In vivo labeling of amyloid with BF-108. Neurosci Res 2004; 48: 65-74.
20. Okamura N, Suemoto T, Shimadzu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci 2004; 24: 2535-2541.
21. Okamura N, Suemoto T, Shiomitsu T, et al. A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J Mol Neurosci 2004; 24: 247-255.
22. Furumoto S, Okamura N, Iwata R, Yanai Y, Arai H, Kudo Y. Recent advances in the development of amyloid imaging agents. Curr Top Med Chem 2007; 7: 1773-1789.
23. Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-Dimethyl-aminothiazol-5-yl]ethenyl)-6 (2-fluoro]ethoxy)benzoxazole a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007; 48: 553-561.
24. Okamura. N, Furumoto S, Funaki Y, et al. Binding and safety profile of novel benzoxazole derivative for in vivo imaging of amyloid deposits in Alzheimer's disease. Geriatr Gerontol Int 2007 (in press)
25. Smalt GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355: 2652-2663.
26. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665-672.
27. Boxer AL, Rabinovici GD, Kepe V, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 2007; 69: 283-290.
28. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab 2002; 22: 1035-1041.
29. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's. disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
30. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid, binding in humans using PET imaging rd Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-1547.
31. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-1972.
32. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007; 68: 1718-1725.
33. 11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-1606.
34. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2007 (in press)
35. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
36. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta 42 in humans. Ann Neurol 2006; 59: 512-519.
37. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844.
38. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-434.
39. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-234.
40. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866.
41. 11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12: 584-595.
42. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991; 1: 103-116.
43. Cummings JL, Cole G. Alzheimer disease. JAMA 2002; 287: 2335-2338.
44. Small GW, Agdeppa ED, Kepe V, Satyamurthy N, Huang SC, Barrio JR. In vivo brain imaging of tangle burden in humans. J Mol Neurosci 2002; 19: 323-327.
45. Okamura N, Suemoto T, Furumoto S, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 2005; 25: 10857-10862.